In this episode, Matt explores the significance of IL-11, a proinflammatory cytokine involved in processes like blood cell production, bone health, and tissue repair, and its impact on inflammation and immune responses. He discusses a recent study showing that administering an anti-IL-11 drug to older mice extended their median lifespan, sparking interest in the geroscience community. Matt also covers related pathways (ERK, AMPK, and mTOR), genetic and pharmacological models of IL-11 reduction, and shares his thoughts on the paper's potential impact on longevity research, highlighting questions for future studies.

Key Points:

Matt explores the function of IL-11 in the body, discussing its connection to longevity research. He reviews a recent study on anti-IL-11 drugs extending lifespan in older mice and offers insights into the implications for future research.

• Breakthrough Study: Matt discusses a new paper showing that inhibiting IL-11, a pro-inflammatory molecule, can extend the lifespan and healthspan in mice.
• IL-11's Role: IL-11 is linked to ageing, increasing inflammation, and negatively affecting metabolism and tissue health as we grow older.
• Promising Longevity Effects: The study found that both genetic deletion and antibody treatments targeting IL-11 led to lifespan extensions in mice, with results comparable to rapamycin, a well-known longevity drug.
• Impact on Metabolism: Blocking IL-11 improved metabolism and muscle function in aged mice, suggesting potential benefits beyond just longevity.
• Cautious Optimism: While the findings are promising, Matt urges caution, as further studies are needed to determine side effects and confirm whether these results apply to humans.
• Future Applications: Matt suggests that clinical trials and studies on IL-11 in humans and companion animals could provide quick insights into its potential as a longevity treatment.